Athira Pharma Inc - ESG Rating & Company Profile powered by AI
Comprehensive Sustainability analysis of Athira Pharma Inc are accessed by signing in. This page includes a questions and answers section about Athira Pharma Inc. The webpage displays a free Environmental, Social and Governance analysis covering Athira Pharma Inc.
Athira Pharma Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.0
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Athira Pharma Inc | 8.0 | High |
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Athira Pharma Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Athira Pharma Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Athira Pharma Inc report the average age of the workforce?
Sign up for free to unlockDoes Athira Pharma Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Athira Pharma Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Athira Pharma Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Athira Pharma Inc offer flexible work?
Sign up for free to unlockDoes Athira Pharma Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Athira Pharma Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Athira Pharma Inc conduct supply chain audits?
Sign up for free to unlockDoes Athira Pharma Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Athira Pharma Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Athira Pharma Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Athira Pharma Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Athira Pharma Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Athira Pharma Inc disclose water use targets?
Sign up for free to unlockDoes Athira Pharma Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Athira Pharma Inc have a product recall in the last two years?
Sign up for free to unlockDoes Athira Pharma Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Athira Pharma Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Athira Pharma Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Athira Pharma Inc disclose parental leave metrics?
Sign up for free to unlockDoes Athira Pharma Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Athira Pharma Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Athira Pharma Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Athira Pharma Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Athira Pharma Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Athira Pharma Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Athira Pharma Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Athira Pharma Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Athira Pharma Inc disclose its waste policy?
Sign up for free to unlockDoes Athira Pharma Inc report according to TCFD requirements?
Sign up for free to unlockDoes Athira Pharma Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Athira Pharma Inc disclose energy use targets?
Sign up for free to unlockDoes Athira Pharma Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Athira Pharma Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Athira Pharma Inc
These potential risks are based on the size, segment and geographies of the company.
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease. The company also develops product candidates, which are in preclinical stage, including ATH-1019/ATH-1020 for neuropsychiatric conditions; and ATH-1018 for peripheral nervous system disorders, such as neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.